false --09-30 2024 Q2 0001827855 0 0 0 0 0 0 0 0001827855 2023-10-01 2024-03-31 0001827855 2024-05-14 0001827855 2024-03-31 0001827855 2023-09-30 0001827855 2024-01-01 2024-03-31 0001827855 2023-01-01 2023-03-31 0001827855 2022-10-01 2023-03-31 0001827855 us-gaap:CommonStockMember 2022-09-30 0001827855 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001827855 us-gaap:RetainedEarningsMember 2022-09-30 0001827855 2022-09-30 0001827855 us-gaap:CommonStockMember 2022-12-31 0001827855 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001827855 us-gaap:RetainedEarningsMember 2022-12-31 0001827855 2022-12-31 0001827855 us-gaap:CommonStockMember 2023-09-30 0001827855 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001827855 us-gaap:RetainedEarningsMember 2023-09-30 0001827855 us-gaap:CommonStockMember 2023-12-31 0001827855 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001827855 us-gaap:RetainedEarningsMember 2023-12-31 0001827855 2023-12-31 0001827855 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001827855 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001827855 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001827855 2022-10-01 2022-12-31 0001827855 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001827855 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001827855 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001827855 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001827855 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001827855 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001827855 2023-10-01 2023-12-31 0001827855 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001827855 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001827855 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001827855 us-gaap:CommonStockMember 2023-03-31 0001827855 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001827855 us-gaap:RetainedEarningsMember 2023-03-31 0001827855 2023-03-31 0001827855 us-gaap:CommonStockMember 2024-03-31 0001827855 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001827855 us-gaap:RetainedEarningsMember 2024-03-31 0001827855 2021-10-01 2022-09-30 0001827855 2022-01-01 2022-12-28 0001827855 MCLE:AlboroviMember 2023-12-31 0001827855 MCLE:AlboroviMember 2023-09-30 0001827855 MCLE:ZuMember 2024-03-31 0001827855 MCLE:ZuMember 2023-09-30 0001827855 MCLE:ConvertibleNote1Member 2023-12-31 0001827855 MCLE:ConvertibleNote1Member 2023-10-01 2023-12-31 0001827855 MCLE:ConvertibleNote2Member 2023-10-01 2023-12-31 0001827855 MCLE:ConvertibleNote1Member 2024-01-01 2024-03-31 0001827855 MCLE:ConvertibleNote2Member 2023-12-31 0001827855 MCLE:ConvertibleNote2Member 2024-01-01 2024-03-31 0001827855 MCLE:ConvertibleNote3Member 2023-12-31 0001827855 MCLE:ConvertibleNote3Member 2023-10-01 2023-12-31 0001827855 MCLE:ConvertibleNote3Member 2024-01-01 2024-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

Mark One

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2024

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______ to _______

 

Commission File No. 333-250025

 

Medicale Corp.

(Exact name of registrant as specified in its charter)

 

Nevada 8000 EIN 98-1556944

(State or other jurisdiction of

incorporation or Organization)

(Primary Standard Industrial

Classification Code Number)

(IRS Employer

Identification Number)

 

9314 Forest Hill Blvd #929

Wellington, FL 33411

(407) 245-7339

medicalecorp@gmail.com

(Address, including zip code, and telephone number,

including area code, of registrant’s principal executive offices)

 

Incorp Services, Inc.

3773 Howard Hughes Parkway Suite 500 S

Las Vegas, NV 89169-6014

+1 (702) 866-2500

(Name, address and telephone number of agent for service)

 

Indicate by checkmark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
Emerging growth company ☒    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the most practicable date:

 

Class Outstanding as of May 14, 2024
Common Stock: $0.0001 5,920,000

 

 

   

 

 

TABLE OF CONTENTS

 

PART 1. FINANCIAL INFORMATION  
     
Item 1. Financial Statements (Unaudited) 3
     
  Condensed Balance Sheets as of March 31, 2024 (Unaudited) and September 30, 2023 3
  Condensed Statement of Operations for the three and six months ended March 31, 2024 and 2023 (Unaudited) 4
  Condensed Statement of Stockholders’ Equity (Deficit) for the three and six months ended March 31, 2024 and 2023 (Unaudited) 5
  Condensed Statement of Cash Flows for the three and six months ended March 31, 2024 and 2023 (Unaudited) 6
  Notes to the Condensed Financial Statements (Unaudited) 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 12
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 14
     
Item 4. Controls and Procedures 14
     
PART II. OTHER INFORMATION 15
     
Item 1. Legal Proceedings 15
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 15
     
Item 3. Defaults Upon Senior Securities 15
     
Item 4. Mine Safety Disclosures 15
     
Item 5. Other Information 15
     
Item 6. Exhibits 15
     
  Signatures 16
       

 

 

 

 2 

 

 

PART I. FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

MEDICALE CORP.

CONDENSED BALANCE SHEETS

 

 

   March 31,
2024		   September 30,
2023		 
   (Unaudited)     
         
ASSETS          
           
Current Assets          
Cash  $159   $159 
Total Current Assets   159    159 
           
Total Assets  $159   $159 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
Current Liabilities          
Related party advances  $–   $20,480 
Accounts payable and accrued expenses   962    8,399 
Current liabilities from discontinued operations   12,000    12,000 
           
Total Current Liabilities   12,962    40,879 
           
Long term Liabilities          
Non-Current Convertible Note Payable   58,788    – 
Total Long-term Liabilities   58,788    – 
           
Total Liabilities   71,750    40,879 
           
Stockholders’ Deficit          
Common stock, par value $0.0001; 75,000,000 shares authorized, 5,920,000 shares issued and outstanding at March 31, 2024, and September 30, 2023   592    592 
Additional paid-in capital   76,320    76,320 
Accumulated deficit   (148,503)   (117,632)
Total Stockholders’ Deficit   (71,591)   (40,720)
           
Total Liabilities and Stockholders’ Deficit  $159   $159 

 

The accompanying notes are an integral part of these condensed financial statements.

 

 

 

 3 

 

  

MEDICALE CORP.

CONDENSED STATEMENT OF OPERATIONS

(Unaudited)

 

                     
  

Three months ended

March 31, 2024

  

Three months ended

March 31, 2023

  

Six months
ended

March 31, 2024

  

Six months
ended

March 31, 2023

 
                     
General and Administrative Expenses  $10,603   $6,115   $29,910   $14,829 
                     
NET LOSS FROM OPERATIONS   (10,603)   (6,115)   (29,910)   (14,829)
                     
Other expenses                    
Interest expense   961    –    961    – 
TOTAL OTHER EXPENSES   961    –    961    – 
                     
Loss before taxes   (11,564)   (6,115)   (30,871)   (14,829)
Provision for taxes   –    –    –    – 
Loss from continuing operations   –    –    –    – 
                     
Income (loss) from discontinued operations   –    –    –    455 
                     
NET LOSS  $(11,564)  $(6,115)  $(30,871)  $(14,374)
                     
NET LOSS PER SHARE: BASIC AND DILUTED                    
FROM CONTINUING OPERATION  $(0.00)  $(0.00)  $(0.00)  $(0.00)
FROM DISCONTINUED OPERATION  $0.00   $(0.00)  $(0.01)  $(0.00)
                     
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED   5,920,000    5,920,000    5,920,000    5,920,000 

 

The accompanying notes are an integral part of these condensed financial statements.

 

 

 

 4 

 

 

MEDICALE CORP.

STATEMENT OF STOCKHOLDERS' DEFICIT

For the three and six months ended March 31, 2024 and 2023

(Unaudited)

                     
   Common Stock  

Additional

Paid-in

   Accumulated  

Total

Stockholder’s

 
   Shares   Amount   Capital   Deficit   Deficit 
                     
Balance, September 30, 2022   5,920,000   $592   $25,128   $(80,494)  $(54,774)
Debt forgiveness by related party   –    –    51,192    –    51,192 
Net loss for the period ended December 31, 2022   –    –    –    (8,259)   (8,259)
Balance, December 31, 2022   5,920,000   $592   $76,320    (88,753)  $(11,841)
Net loss for the period ended March 31, 2023   –    –    –    (6,115)   (6,115)
Balance, March 31, 2023   5,920,000   $592    76,320    (94,868)  $(17,956)
                          
                          
                          
                          
                          

Balance, September 30, 2023

   5,920,000   $592   $76,320   $(117,632)  $(40,720)
Net loss for the period ended December 31, 2023   –    –    –    (19,307)   (19,307)
Balance, December 31, 2023   5,920,000   $592   $76,320   $(136,939)  $(60,027)
Net loss for the period ended March 31, 2024   –    –    –    (11,564)   (11,564)
Balance, March 31, 2024   5,920,000   $592   $76,320    (148,503)  $(71,591)

 

The accompanying notes are an integral part of these condensed financial statements.

 

 

 

 5 

 

 

MEDICALE CORP.

CONDENSED STATEMENT OF CASH FLOWS

(Unaudited)

 

         
   Six months
ended
March 31, 2024		   Six months
ended
March 31, 2023		 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net Loss for the period  $(30,871)  $(14,829)
Net Loss for the period from discontinued operation   –    455 
           
Changes in assets and liabilities:          
Accounts payable and accrued liabilities   (7,437)   9,115 
Related party short term advance   (20,480)   – 
CASH FLOWS USED IN OPERATING ACTIVITIES   (58,788)   (5,259)
           
CASH FLOWS FROM INVESTING ACTIVITIES   –    – 
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from Convertible note   58,788    – 
Proceeds from related party short term advances   –    5,418 
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES   58,788    5,418 
           
Net Cash Increase for Period   –    159 
Cash at the beginning of Period   159    – 
Cash at end of Period  $159   $159 
           
SUPPLEMENTAL CASH FLOW INFORMATION:          
Interest paid  $–   $– 
Non-cash investing and financing activities:          
Debt forgiveness by related party  $–   $51,192 

 

The accompanying notes are an integral part of these condensed financial statements.

 

 

 

 6 

 

 

MEDICALE CORP.

Notes to the Condensed Financial Statements

March 31, 2024 and 2023

(Unaudited)

 

 

Note 1 – ORGANIZATION AND NATURE OF BUSINESS

 

MEDICALE CORP (“the Company,”, “we,” “us” or “our”) was incorporated in the State of Nevada on August 17, 2020. We plan to offer consulting services and distribution of the dietary supplements. A dietary supplement is a manufactured product intended to supplement the diet when taken by mouth as a pill, capsule, tablet, or liquid. A supplement can provide nutrients either extracted from food sources or synthetic, individually or in combination, in order to increase the quantity of their consumption.

 

On December 28, 2022, the previous majority shareholder of Medicale Corp. (the “Company”) Borisi Alborovi entered into a stock purchase agreement for the sale of 3,200,000 shares of Common Stock of the Company (the “Shares”) to Magenta Acres, Inc.

 

As a result of the acquisition of the Shares, Magenta Acres Inc. holds approximately 54% of the issued and outstanding shares of Common Stock of the Company, and as such it is able to unilaterally control the election of our board of directors, all matters upon which shareholder approval is required and, ultimately, the direction of our Company.

 

On December 28, 2022, the previous sole officer and director of the Company, Borisi Alborovi, resigned his positions with the Company. Upon such resignations, Chen Zu De was appointed as Chief Executive Officer, Chairman of the Board, Treasurer and Secretary, and Director of the Company.

 

As of the date of this report, the Company had not yet commenced any operations. All activity through the date of this report relates to preserving cash, attempting to raise capital, and continuing the Company’s public reporting.

 

Our principal place of business is located 9314 Forest Hill Blvd #929 Wellington, FL 33411 which is provided to us on a rent free basis by our sole officer and director. Our telephone number is (407) 245-7339.

 

Note 2 – GOING CONCERN

 

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of $148,503 as of March 31, 2024 and $117,632 as of September 30, 2023. The Company currently has losses and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself so that it will be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

 

Note 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited condensed financial statements have been prepared in accordance with the rules and regulations (Regulation S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the three and six months ended March 31, 2024 are not necessarily indicative of the operating results that may be expected for the year ending September 30, 2024. These unaudited condensed financial statements should be read in conjunction with the September 30, 2023, financial statements and notes thereto.

 

 

 

 7 

 

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

  

Deferred Offering Costs

 

Financial Accounting Standard Board Accounting Standards Codification number 340-10-S99-1, Other Assets and Deferred Costs, allows specific, incremental costs directly related to securities offerings to be deferred and charged against the gross proceed of the offering. The Company defers applicable syndication expenses based on these criteria. The Company will write off all deferred offering costs if a securities offering is aborted.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.

 

Fair Value of Financial Instruments

 

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820 "Fair Value Measurement" defines fair value as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standards apply to recurring and nonrecurring fair value measurements of financial and non-financial assets and liabilities. The Company determines the fair values of its assets and liabilities based on a fair value hierarchy that includes three levels of inputs that may be used to measure fair value.

 

For The three levels are defined as follows:

 

Level 1: defined as observable inputs such as quoted prices in active markets;
Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and
Level 3: defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

 

Due to its short-term nature, the carrying value of receivables, accounts payable, and advances approximated fair value at December 31, 2023.

 

Revenue Recognition

 

The Company follows the guidance of Accounting Standards Codification (ASC) 606, Revenue from Contracts. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients.

 

All revenue generated by the Company was done so by operations that have been discontinued.

 

 

 

 8 

 

 

Income Taxes

 

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

 

Long-Lived Assets – Intangible Assets

 

We account for our intangible assets in accordance with ASC Subtopic 350-30, General Intangibles Other Than Goodwill, and ASC Subtopic 360-10-05, Accounting for the Impairment or Disposal of Long-Lived Assets. ASC Subtopic 350-30 requires assets to be measured based on the fair value of the consideration given or the fair value of the assets (or net assets) acquired, whichever is more clearly evident and, thus, more reliably measurable. Further, ASC Subtopic 350-30 requires an intangible asset to be amortized over its useful life and for the useful life to be evaluated every reporting period to determine whether events or circumstances warrant a revision to the remaining period of amortization. If the estimate of useful life is changed the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Costs of internally developing, maintaining, or restoring intangible assets are recognized as an expense when incurred.

 

Basic Income (Loss) Per Share

 

The Company computes income (loss) per share in accordance with FASB ASC 260 “Earnings per Share.” Basic loss per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted income (loss) per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. As of March 31, 2024, there were no potentially dilutive debt or equity instruments issued or outstanding.

 

Recent Accounting Pronouncements

 

We have reviewed all the recently issued, but not yet effective, accounting pronouncements and we do not believe any of these pronouncements will have a material impact on the Company.

 

Risks and Uncertainties

 

In December 2020, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China. While initially the outbreak was largely concentrated in China and caused significant disruptions to its economy, it has now spread to several other countries and infections have been reported globally.

 

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but is anticipated to have a material adverse impact on our business, financial condition and results of operations.

 

Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.

 

 

 

 9 

 

 

Financial Statement Reclassification

 

Certain account balances from prior periods have been reclassified in these financial statements to conform to current period classifications.

 

Note 4 – DISCONTINUED OPERATION

 

Through December 31, 2022, the Company’s primary business was the sale of various consumer products and accessories. As of January 1, 2023, the Company ceased operations. On January 9, 2023, a change in control completed as the Company’s former majority shareholder sold his 3,200,000 shares to an investor group. After the change in control, the Company’s operations are determined by the new investor group. As such, the Company accounted for all of its revenue (loss), liabilities and results of operations up to January 1, 2023 as discontinued operations.

 

The Company has reclassified its previously issued financial statements to segregate the discontinued operations as of the earliest period reported.

 

The following table presents information related to the liabilities that were classified as current liabilities from discontinued operations in our balance sheets: 

Schedule of discontinued operations - balance sheet  March 31, 2024   September 30, 2023 
   (Unaudited)     
         
Current Liabilities          
Accounts payable and accrued expenses  $12,000   $12,000 
           
Total current liabilities from discontinued operations  $12,000   $12,000 

 

As of March 31 2024 and 2023 the company has not generate any revenue from discontinued operation.

 

Note 5 – COMMON STOCK

 

The Company has 75,000,000, $0.0001 par value shares of voting common stock authorized.

 

All shares of common stock have voting rights and are identical. All holders of shares of common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock held by such stockholder.

 

On December 28, 2022, Borisi Alborovi, the previous majority shareholder of Medicale Corp. (the “Company”), entered into a stock purchase agreement for the sale of 3,200,000 shares of Common Stock of the Company (the “Shares”) to Magenta Acres, Inc.

 

As of March 31, 2024 the company had 5,920,000 shares issued and outstanding.

 

Voting Common Stock

 

All shares of common stock have voting rights and are identical. All holders of shares of voting common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock held by such stockholder. 

 

Non-voting Common Stock

 

All of the other terms of the Non-Voting Common Stock shall be identical to the Voting Common Stock, except for the right of first refusal that attaches to the Non-Voting Common Stock, as explained in the Company’s Bylaws.

 

 

 

 10 

 

 

Note 6 – INTANGIBLE ASSETS

 

The Company purchased and possesses an asset in a form of an operative website with news blog. The Company purchased the website for $12,000 and was amortizing the asset straight-line over its five-year useful life or $2,400 per year. Due to the impairment evaluation analysis as of September 30, 2022 where we deemed the asset’s carrying amount was not recoverable, we recognized impairment of $7,200, leaving the Intangible Assets with the Net Book Value of $nil as of March 31, 2024 and September 30, 2023.

 

Note 7 – COMMITMENTS AND CONTINGENCIES

 

Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.

 

Note 8 – RELATED PARTY TRANSACTIONS

 

The sole officer and director, Borisi Alborovi, was the only related party with whom the Company had transactions with during the period from inception on August 17, 2020 through December 31, 2022.

 

On December 28, 2022, the previous sole officer and director, Borisi Alborovi, resigned his positions with the Company. Upon such resignations, Chen Zu De was appointed as Chief Executive Officer, Chairman of the Board, Treasurer and Secretary, and Director of the Company.

 

As a result of the acquisition of the Shares on December 28, 2022, the previous majority shareholder of Medicale Corp. (the “Company”) Borisi Alborovi forgive the debt that due to him, with the amount of $51,192.

 

As of December 31, 2023 and September 30, 2023, the Company owed Mr. Alborovi $nil and $nil respectively, for operating expenses on behalf of the Company. The amounts due to the related party are unsecured and non-interest bearing with no set terms of repayment.

 

As of March 31, 2024 and September 30, 2023, the Company owed Chen Zu De $nil and $nil respectively, for operating expenses on behalf of the Company. The amounts due to the related party are unsecured and non-interest bearing with no set terms of repayment.

 

Note 9 – CONVERTIBLE NOTE PAYABLE

 

On December 31, 2023, the company entered into a Convertible Note agreement with an third party at $21,051. The note bears a 8% interest rate per year and matures on December 31, 2029. The note can be converted to the Company’s common stock at $0.01 per share. As of March 31, 2024, the accrued interest is $420.

 

On December 31, 2023, the company entered into a Convertible Note agreement with an third party at $27,135. The note bears a 8% interest rate per year and matures on December 31, 2029. The note can be converted to the Company’s common stock at $0.01 per share. As of March 31, 2024, the accrued interest is $541.

 

On March 31, 2024, the company entered into a Convertible Note agreement with an third party at $10,602. The note bears a 8% interest rate per year and matures on March 31, 2030. The note can be converted to the Company’s common stock at $0.01 per share. As of March 31, 2024, the accrued interest is $nil.

 

Note 10 – SUBSEQUENT EVENTS

  

In accordance with SFAS 165 (ASC 855-10) the Company has analyzed its operations subsequent to March 31, 2024 to the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these financial statements.

 

 

 

 11 

 

 

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

 

FORWARD LOOKING STATEMENTS

 

Statements made in this Form 10-Q that are not historical or current facts are “forward-looking statements” made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 (the “Act”) and Section 21E of the Securities Exchange Act of 1934. These statements often can be identified by the use of terms such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “approximate” or “continue,” or the negative thereof. We intend that such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

 

Employees and Employment Agreements

 

At present, we have no employees other than our officer and director. We presently do not have pension, health, annuity, insurance, stock options, profit sharing or similar benefit plans; however, we may adopt such plans in the future. There are presently no personal benefits available to any officers, directors or employees.

 

Results of Operation

 

Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.

 

We expect we will require additional capital to meet our long term operating requirements. We expect to raise additional capital through, among other things, the sale of equity or debt securities.

 

Three Months Ended March 31, 2024 and 2023:

 

During the three months ended March 31, 2024 and 2023 the Company’s net income from discontinued operations were $nil.

 

Our net loss for the three months ended March 31, 2024 was $11,564. Operating expenses consist of mainly professional fees.

 

Our net loss for the three months ended March 31, 2023 was $6,115. Operating expenses consist of mainly professional fees.

 

Six Months Ended March 31, 2024 and 2023:

 

During the six months ended March 31, 2024 and 2023 the Company’s net income from discontinued operations were $nil and $455.

 

Our net loss for the six months ended March 31, 2024 was $30,871. Operating expenses consist of mainly professional fees.

 

Our net loss for the six months ended March 31, 2023 was $14,829. Operating expenses consist of mainly professional fees.

 

 

 

 12 

 

  

Liquidity and Capital Resources

 

As of March 31, 2024, our total assets were $159 consisting of cash of $159. As of March 31, 2023, our current liabilities were $962, and current liabilities from discontinued operations of $12,000.

 

Cash Flows from Operating Activities

 

We have not generated positive cash flows from operating activities. For the six months ended March 31, 2024 and 2023, net cash flows used in operating activities were $58,788 and $5,259, respectively.

 

Cash Flows from Investing Activities

 

We have not generated cash flows from investing activities during the six months ended March 31, 2024 and 2023, respectively.

 

Cash Flows from Financing Activities

 

We have generated cash flows from financing activities in the amount $58,788 and $5,418 during the six months ended March 31, 2024 and 2023, respectively.

 

Plan of Operation and Funding

 

We expect that working capital requirements will continue to be funded through a combination of our existing funds and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business.

 

Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next three months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) acquisition of inventory; (ii) developmental expenses associated with a start-up business; and (iii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations. We will have to raise additional funds in the next twelve months in order to sustain and expand our operations. We currently do not have a specific plan of how we will obtain such funding; however, we anticipate that additional funding will be in the form of equity financing from the sale of our common stock. We have and will continue to seek to obtain short-term loans from our directors, although no future arrangement for additional loans has been made. We do not have any agreements with our directors concerning these loans. We do not have any arrangements in place for any future equity financing.

 

 

 

 13 

 

 

Off-Balance Sheet Arrangements

 

As of the date of this Quarterly Report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 

Going Concern

 

The financial statements have been prepared “assuming that we will continue as a going concern,” which contemplates that we will realize our assets and satisfy our liabilities and commitments in the ordinary course of business.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

No report required.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2024. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Such officer also confirmed that there was no change in our internal control over financial reporting during the three and six months period ended March 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

 

 14 

 

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

Management is not aware of any legal proceedings contemplated by any governmental authority or any other party involving us or our properties. As of the date of this Quarterly Report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. Management is not aware of any other legal proceedings pending or that have been threatened against us or our properties.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

No report required.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

No report required.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

During the quarter ended March 31, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.

 

ITEM 6. EXHIBITS

 

31 Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002
32 Certification of the Chief Executive Officer and the Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002
101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101)

 

 

 

 15 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in 9314 Forest Hill Blvd #929, Wellington, FL 33411.

 

 

 

  MEDICALE CORP.
   
   
  By: /s/ J. Chen Zu De  
 

 

President, Treasurer, Secretary and Director

(Principal Executive, Financial and Accounting Officer)

   

 

 

In accordance with the requirements of the Securities Act of 1933, this registration statement was signed by the following persons in the capacities and on the dates stated.

 

Signature   Title   Date
         
         
/s/ J. Chen Zu De        
Chen Zu De  

President, Treasurer, Secretary and Director

(Principal Executive, Financial and Accounting Officer)

   May 14, 2024

 

  

 

 

 

 

 

 16 

Exhibit 31

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT 2002

 

I, Chen Zu De, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Medicale Corp.

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures, to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

 

b.  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.  Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b.  any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: May 14, 2024

 

/s/ Chen Zu De                      

Chen Zu De

Chief Executive Officer

Chief Financial Officer

Exhibit 32

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

The undersigned officer of Medicale Corp. (the “Company”), hereby certifies, to such officer's knowledge, that the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

/s/ Chen Zu De                              

Chen Zu De

Chief Executive Officer

Chief Financial Officer

 

 

May 14, 2024

v3.24.1.1.u2
Cover - shares
 6 Months Ended
Mar. 31, 2024
May 14, 2024
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2024  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2024  
Current Fiscal Year End Date --09-30  
Entity File Number 333-250025  
Entity Registrant Name Medicale Corp.  
Entity Central Index Key 0001827855  
Entity Tax Identification Number 98-1556944  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 9314 Forest Hill Blvd #92  
Entity Address, City or Town Wellington  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33411  
City Area Code 407  
Local Phone Number 245-7339  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   5,920,000
v3.24.1.1.u2
Condensed Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2024
Sep. 30, 2023
Current Assets    
Cash $ 159 $ 159
Total Current Assets 159 159
Total Assets 159 159
Current Liabilities    
Related party advances 0 20,480
Accounts payable and accrued expenses 962 8,399
Current liabilities from discontinued operations 12,000 12,000
Total Current Liabilities 12,962 40,879
Long term Liabilities    
Non-Current Convertible Note Payable 58,788 0
Total Long-term Liabilities 58,788 0
Total Liabilities 71,750 40,879
Stockholders’ Deficit    
Common stock, par value $0.0001; 75,000,000 shares authorized, 5,920,000 shares issued and outstanding at March 31, 2024, and September 30, 2023 592 592
Additional paid-in capital 76,320 76,320
Accumulated deficit (148,503) (117,632)
Total Stockholders’ Deficit (71,591) (40,720)
Total Liabilities and Stockholders’ Deficit $ 159 $ 159
v3.24.1.1.u2
Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2024
Sep. 30, 2023
Statement of Financial Position [Abstract]    
Common Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Common Stock, Shares Authorized 75,000,000 75,000,000
Common Stock, Shares, Issued 5,920,000 5,920,000
Common Stock, Shares, Outstanding 5,920,000 5,920,000
v3.24.1.1.u2
Statements of Operations - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]        
General and Administrative Expenses $ 10,603 $ 6,115 $ 29,910 $ 14,829
NET LOSS FROM OPERATIONS (10,603) (6,115) (29,910) (14,829)
Other expenses        
Interest expense 961 0 961 0
TOTAL OTHER EXPENSES 961 0 961 0
Loss before taxes (11,564) (6,115) (30,871) (14,829)
Provision for taxes 0 0 0 0
Loss from continuing operations 0 0 0 0
Income (loss) from discontinued operations 0 0 0 455
NET LOSS $ (11,564) $ (6,115) $ (30,871) $ (14,374)
v3.24.1.1.u2
Statements of Operations (Parenthetical) - $ / shares
 3 Months Ended 6 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]        
Income (Loss) from Continuing Operations, Per Basic Share $ (0.00) $ (0.00) $ (0.00) $ (0.00)
Income (Loss) from Continuing Operations, Per Diluted Share (0.00) (0.00) (0.00) (0.00)
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 0.00 (0.00) (0.01) (0.00)
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share $ 0.00 $ (0.00) $ (0.01) $ (0.00)
Weighted Average Number of Shares Outstanding, Basic 5,920,000   5,920,000 5,920,000
Weighted Average Number of Shares Outstanding, Diluted 5,920,000 5,920,000 5,920,000 5,920,000
v3.24.1.1.u2
Statement of Stockholders Equity (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Sep. 30, 2022 $ 592 $ 25,128 $ (80,494) $ (54,774)
Shares, Outstanding, Beginning Balance at Sep. 30, 2022 5,920,000      
Debt forgiveness by related party 51,192 51,192
Net loss (8,259) (8,259)
Ending balance, value at Dec. 31, 2022 $ 592 76,320 (88,753) (11,841)
Shares, Outstanding, Ending Balance at Dec. 31, 2022 5,920,000      
Beginning balance, value at Sep. 30, 2022 $ 592 25,128 (80,494) (54,774)
Shares, Outstanding, Beginning Balance at Sep. 30, 2022 5,920,000      
Net loss       (14,374)
Ending balance, value at Mar. 31, 2023 $ 592 76,320 (94,868) (17,956)
Shares, Outstanding, Ending Balance at Mar. 31, 2023 5,920,000      
Beginning balance, value at Dec. 31, 2022 $ 592 76,320 (88,753) (11,841)
Shares, Outstanding, Beginning Balance at Dec. 31, 2022 5,920,000      
Net loss (6,115) (6,115)
Ending balance, value at Mar. 31, 2023 $ 592 76,320 (94,868) (17,956)
Shares, Outstanding, Ending Balance at Mar. 31, 2023 5,920,000      
Beginning balance, value at Sep. 30, 2023 $ 592 76,320 (117,632) (40,720)
Shares, Outstanding, Beginning Balance at Sep. 30, 2023 5,920,000      
Net loss (19,307) (19,307)
Ending balance, value at Dec. 31, 2023 $ 592 76,320 (136,939) (60,027)
Shares, Outstanding, Ending Balance at Dec. 31, 2023 5,920,000      
Beginning balance, value at Sep. 30, 2023 $ 592 76,320 (117,632) (40,720)
Shares, Outstanding, Beginning Balance at Sep. 30, 2023 5,920,000      
Net loss       (30,871)
Ending balance, value at Mar. 31, 2024 $ 592 76,320 (148,503) (71,591)
Shares, Outstanding, Ending Balance at Mar. 31, 2024 5,920,000      
Beginning balance, value at Dec. 31, 2023 $ 592 76,320 (136,939) (60,027)
Shares, Outstanding, Beginning Balance at Dec. 31, 2023 5,920,000      
Net loss (11,564) (11,564)
Ending balance, value at Mar. 31, 2024 $ 592 $ 76,320 $ (148,503) $ (71,591)
Shares, Outstanding, Ending Balance at Mar. 31, 2024 5,920,000      
v3.24.1.1.u2
Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES        
Net Loss for the period $ (11,564) $ (6,115) $ (30,871) $ (14,829)
Net Loss for the period from discontinued operation 0 0 0 455
Changes in assets and liabilities:        
Accounts payable and accrued liabilities     (7,437) 9,115
Related party short term advance     (20,480) 0
CASH FLOWS USED IN OPERATING ACTIVITIES     (58,788) (5,259)
CASH FLOWS FROM FINANCING ACTIVITIES        
Proceeds from Convertible note     58,788 0
Proceeds from related party short term advances     0 5,418
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES     58,788 5,418
Net Cash Increase for Period     0 159
Cash at the beginning of Period     159 0
Cash at end of Period $ 159 $ 159 159 159
SUPPLEMENTAL CASH FLOW INFORMATION:        
Interest paid     0 0
Non-cash investing and financing activities:        
Debt forgiveness by related party     $ 0 $ 51,192
v3.24.1.1.u2
Pay vs Performance Disclosure - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure [Table]            
Net Income (Loss) $ (11,564) $ (19,307) $ (6,115) $ (8,259) $ (30,871) $ (14,374)
v3.24.1.1.u2
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual [Table]  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.24.1.1.u2
ORGANIZATION AND NATURE OF BUSINESS
 6 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND NATURE OF BUSINESS

Note 1 – ORGANIZATION AND NATURE OF BUSINESS

 

MEDICALE CORP (“the Company,”, “we,” “us” or “our”) was incorporated in the State of Nevada on August 17, 2020. We plan to offer consulting services and distribution of the dietary supplements. A dietary supplement is a manufactured product intended to supplement the diet when taken by mouth as a pill, capsule, tablet, or liquid. A supplement can provide nutrients either extracted from food sources or synthetic, individually or in combination, in order to increase the quantity of their consumption.

 

On December 28, 2022, the previous majority shareholder of Medicale Corp. (the “Company”) Borisi Alborovi entered into a stock purchase agreement for the sale of 3,200,000 shares of Common Stock of the Company (the “Shares”) to Magenta Acres, Inc.

 

As a result of the acquisition of the Shares, Magenta Acres Inc. holds approximately 54% of the issued and outstanding shares of Common Stock of the Company, and as such it is able to unilaterally control the election of our board of directors, all matters upon which shareholder approval is required and, ultimately, the direction of our Company.

 

On December 28, 2022, the previous sole officer and director of the Company, Borisi Alborovi, resigned his positions with the Company. Upon such resignations, Chen Zu De was appointed as Chief Executive Officer, Chairman of the Board, Treasurer and Secretary, and Director of the Company.

 

As of the date of this report, the Company had not yet commenced any operations. All activity through the date of this report relates to preserving cash, attempting to raise capital, and continuing the Company’s public reporting.

 

Our principal place of business is located 9314 Forest Hill Blvd #929 Wellington, FL 33411 which is provided to us on a rent free basis by our sole officer and director. Our telephone number is (407) 245-7339.

 
v3.24.1.1.u2
GOING CONCERN
 6 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN

Note 2 – GOING CONCERN

 

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of $148,503 as of March 31, 2024 and $117,632 as of September 30, 2023. The Company currently has losses and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself so that it will be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

 
v3.24.1.1.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 6 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Note 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited condensed financial statements have been prepared in accordance with the rules and regulations (Regulation S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the three and six months ended March 31, 2024 are not necessarily indicative of the operating results that may be expected for the year ending September 30, 2024. These unaudited condensed financial statements should be read in conjunction with the September 30, 2023, financial statements and notes thereto.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

  

Deferred Offering Costs

 

Financial Accounting Standard Board Accounting Standards Codification number 340-10-S99-1, Other Assets and Deferred Costs, allows specific, incremental costs directly related to securities offerings to be deferred and charged against the gross proceed of the offering. The Company defers applicable syndication expenses based on these criteria. The Company will write off all deferred offering costs if a securities offering is aborted.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.

 

Fair Value of Financial Instruments

 

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820 "Fair Value Measurement" defines fair value as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standards apply to recurring and nonrecurring fair value measurements of financial and non-financial assets and liabilities. The Company determines the fair values of its assets and liabilities based on a fair value hierarchy that includes three levels of inputs that may be used to measure fair value.

 

For The three levels are defined as follows:

 

Level 1: defined as observable inputs such as quoted prices in active markets;
Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and
Level 3: defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

 

Due to its short-term nature, the carrying value of receivables, accounts payable, and advances approximated fair value at December 31, 2023.

 

Revenue Recognition

 

The Company follows the guidance of Accounting Standards Codification (ASC) 606, Revenue from Contracts. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients.

 

All revenue generated by the Company was done so by operations that have been discontinued.

 

Income Taxes

 

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

 

Long-Lived Assets – Intangible Assets

 

We account for our intangible assets in accordance with ASC Subtopic 350-30, General Intangibles Other Than Goodwill, and ASC Subtopic 360-10-05, Accounting for the Impairment or Disposal of Long-Lived Assets. ASC Subtopic 350-30 requires assets to be measured based on the fair value of the consideration given or the fair value of the assets (or net assets) acquired, whichever is more clearly evident and, thus, more reliably measurable. Further, ASC Subtopic 350-30 requires an intangible asset to be amortized over its useful life and for the useful life to be evaluated every reporting period to determine whether events or circumstances warrant a revision to the remaining period of amortization. If the estimate of useful life is changed the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Costs of internally developing, maintaining, or restoring intangible assets are recognized as an expense when incurred.

 

Basic Income (Loss) Per Share

 

The Company computes income (loss) per share in accordance with FASB ASC 260 “Earnings per Share.” Basic loss per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted income (loss) per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. As of March 31, 2024, there were no potentially dilutive debt or equity instruments issued or outstanding.

 

Recent Accounting Pronouncements

 

We have reviewed all the recently issued, but not yet effective, accounting pronouncements and we do not believe any of these pronouncements will have a material impact on the Company.

 

Risks and Uncertainties

 

In December 2020, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China. While initially the outbreak was largely concentrated in China and caused significant disruptions to its economy, it has now spread to several other countries and infections have been reported globally.

 

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but is anticipated to have a material adverse impact on our business, financial condition and results of operations.

 

Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.

 

Financial Statement Reclassification

 

Certain account balances from prior periods have been reclassified in these financial statements to conform to current period classifications.

 
v3.24.1.1.u2
DISCONTINUED OPERATION
 6 Months Ended
Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATION

Note 4 – DISCONTINUED OPERATION

 

Through December 31, 2022, the Company’s primary business was the sale of various consumer products and accessories. As of January 1, 2023, the Company ceased operations. On January 9, 2023, a change in control completed as the Company’s former majority shareholder sold his 3,200,000 shares to an investor group. After the change in control, the Company’s operations are determined by the new investor group. As such, the Company accounted for all of its revenue (loss), liabilities and results of operations up to January 1, 2023 as discontinued operations.

 

The Company has reclassified its previously issued financial statements to segregate the discontinued operations as of the earliest period reported.

 

The following table presents information related to the liabilities that were classified as current liabilities from discontinued operations in our balance sheets: 

Schedule of discontinued operations - balance sheet  March 31, 2024   September 30, 2023 
   (Unaudited)     
         
Current Liabilities          
Accounts payable and accrued expenses  $12,000   $12,000 
           
Total current liabilities from discontinued operations  $12,000   $12,000 

 

As of March 31 2024 and 2023 the company has not generate any revenue from discontinued operation.

 
v3.24.1.1.u2
COMMON STOCK
 6 Months Ended
Mar. 31, 2024
Equity [Abstract]  
COMMON STOCK

Note 5 – COMMON STOCK

 

The Company has 75,000,000, $0.0001 par value shares of voting common stock authorized.

 

All shares of common stock have voting rights and are identical. All holders of shares of common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock held by such stockholder.

 

On December 28, 2022, Borisi Alborovi, the previous majority shareholder of Medicale Corp. (the “Company”), entered into a stock purchase agreement for the sale of 3,200,000 shares of Common Stock of the Company (the “Shares”) to Magenta Acres, Inc.

 

As of March 31, 2024 the company had 5,920,000 shares issued and outstanding.

 

Voting Common Stock

 

All shares of common stock have voting rights and are identical. All holders of shares of voting common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock held by such stockholder. 

 

Non-voting Common Stock

 

All of the other terms of the Non-Voting Common Stock shall be identical to the Voting Common Stock, except for the right of first refusal that attaches to the Non-Voting Common Stock, as explained in the Company’s Bylaws.

 
v3.24.1.1.u2
INTANGIBLE ASSETS
 6 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS

Note 6 – INTANGIBLE ASSETS

 

The Company purchased and possesses an asset in a form of an operative website with news blog. The Company purchased the website for $12,000 and was amortizing the asset straight-line over its five-year useful life or $2,400 per year. Due to the impairment evaluation analysis as of September 30, 2022 where we deemed the asset’s carrying amount was not recoverable, we recognized impairment of $7,200, leaving the Intangible Assets with the Net Book Value of $nil as of March 31, 2024 and September 30, 2023.

 
v3.24.1.1.u2
COMMITMENTS AND CONTINGENCIES
 6 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

Note 7 – COMMITMENTS AND CONTINGENCIES

 

Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.

 
v3.24.1.1.u2
RELATED PARTY TRANSACTIONS
 6 Months Ended
Mar. 31, 2024
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

Note 8 – RELATED PARTY TRANSACTIONS

 

The sole officer and director, Borisi Alborovi, was the only related party with whom the Company had transactions with during the period from inception on August 17, 2020 through December 31, 2022.

 

On December 28, 2022, the previous sole officer and director, Borisi Alborovi, resigned his positions with the Company. Upon such resignations, Chen Zu De was appointed as Chief Executive Officer, Chairman of the Board, Treasurer and Secretary, and Director of the Company.

 

As a result of the acquisition of the Shares on December 28, 2022, the previous majority shareholder of Medicale Corp. (the “Company”) Borisi Alborovi forgive the debt that due to him, with the amount of $51,192.

 

As of December 31, 2023 and September 30, 2023, the Company owed Mr. Alborovi $nil and $nil respectively, for operating expenses on behalf of the Company. The amounts due to the related party are unsecured and non-interest bearing with no set terms of repayment.

 

As of March 31, 2024 and September 30, 2023, the Company owed Chen Zu De $nil and $nil respectively, for operating expenses on behalf of the Company. The amounts due to the related party are unsecured and non-interest bearing with no set terms of repayment.

 
v3.24.1.1.u2
CONVERTIBLE NOTE PAYABLE
 6 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
CONVERTIBLE NOTE PAYABLE

Note 9 – CONVERTIBLE NOTE PAYABLE

 

On December 31, 2023, the company entered into a Convertible Note agreement with an third party at $21,051. The note bears a 8% interest rate per year and matures on December 31, 2029. The note can be converted to the Company’s common stock at $0.01 per share. As of March 31, 2024, the accrued interest is $420.

 

On December 31, 2023, the company entered into a Convertible Note agreement with an third party at $27,135. The note bears a 8% interest rate per year and matures on December 31, 2029. The note can be converted to the Company’s common stock at $0.01 per share. As of March 31, 2024, the accrued interest is $541.

 

On March 31, 2024, the company entered into a Convertible Note agreement with an third party at $10,602. The note bears a 8% interest rate per year and matures on March 31, 2030. The note can be converted to the Company’s common stock at $0.01 per share. As of March 31, 2024, the accrued interest is $nil.

 
v3.24.1.1.u2
SUBSEQUENT EVENTS
 6 Months Ended
Mar. 31, 2024
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

Note 10 – SUBSEQUENT EVENTS

  

In accordance with SFAS 165 (ASC 855-10) the Company has analyzed its operations subsequent to March 31, 2024 to the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these financial statements.
v3.24.1.1.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 6 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited condensed financial statements have been prepared in accordance with the rules and regulations (Regulation S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the three and six months ended March 31, 2024 are not necessarily indicative of the operating results that may be expected for the year ending September 30, 2024. These unaudited condensed financial statements should be read in conjunction with the September 30, 2023, financial statements and notes thereto.

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

  
Deferred Offering Costs

Deferred Offering Costs

 

Financial Accounting Standard Board Accounting Standards Codification number 340-10-S99-1, Other Assets and Deferred Costs, allows specific, incremental costs directly related to securities offerings to be deferred and charged against the gross proceed of the offering. The Company defers applicable syndication expenses based on these criteria. The Company will write off all deferred offering costs if a securities offering is aborted.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820 "Fair Value Measurement" defines fair value as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standards apply to recurring and nonrecurring fair value measurements of financial and non-financial assets and liabilities. The Company determines the fair values of its assets and liabilities based on a fair value hierarchy that includes three levels of inputs that may be used to measure fair value.

 

For The three levels are defined as follows:

 

Level 1: defined as observable inputs such as quoted prices in active markets;
Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and
Level 3: defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

 

Due to its short-term nature, the carrying value of receivables, accounts payable, and advances approximated fair value at December 31, 2023.

 
Revenue Recognition

Revenue Recognition

 

The Company follows the guidance of Accounting Standards Codification (ASC) 606, Revenue from Contracts. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients.

 

All revenue generated by the Company was done so by operations that have been discontinued.

 
Income Taxes

Income Taxes

 

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

 
Long-Lived Assets – Intangible Assets

Long-Lived Assets – Intangible Assets

 

We account for our intangible assets in accordance with ASC Subtopic 350-30, General Intangibles Other Than Goodwill, and ASC Subtopic 360-10-05, Accounting for the Impairment or Disposal of Long-Lived Assets. ASC Subtopic 350-30 requires assets to be measured based on the fair value of the consideration given or the fair value of the assets (or net assets) acquired, whichever is more clearly evident and, thus, more reliably measurable. Further, ASC Subtopic 350-30 requires an intangible asset to be amortized over its useful life and for the useful life to be evaluated every reporting period to determine whether events or circumstances warrant a revision to the remaining period of amortization. If the estimate of useful life is changed the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Costs of internally developing, maintaining, or restoring intangible assets are recognized as an expense when incurred.

 
Basic Income (Loss) Per Share

Basic Income (Loss) Per Share

 

The Company computes income (loss) per share in accordance with FASB ASC 260 “Earnings per Share.” Basic loss per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted income (loss) per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. As of March 31, 2024, there were no potentially dilutive debt or equity instruments issued or outstanding.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

We have reviewed all the recently issued, but not yet effective, accounting pronouncements and we do not believe any of these pronouncements will have a material impact on the Company.

 
Risks and Uncertainties

Risks and Uncertainties

 

In December 2020, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China. While initially the outbreak was largely concentrated in China and caused significant disruptions to its economy, it has now spread to several other countries and infections have been reported globally.

 

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but is anticipated to have a material adverse impact on our business, financial condition and results of operations.

 

Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.

 
Financial Statement Reclassification

Financial Statement Reclassification

 

Certain account balances from prior periods have been reclassified in these financial statements to conform to current period classifications.

 
v3.24.1.1.u2
DISCONTINUED OPERATION (Tables)
 6 Months Ended
Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of discontinued operations - balance sheet
Schedule of discontinued operations - balance sheet  March 31, 2024   September 30, 2023 
   (Unaudited)     
         
Current Liabilities          
Accounts payable and accrued expenses  $12,000   $12,000 
           
Total current liabilities from discontinued operations  $12,000   $12,000 
v3.24.1.1.u2
GOING CONCERN (Details Narrative) - USD ($)
Mar. 31, 2024
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Retained Earnings (Accumulated Deficit) $ 148,503 $ 117,632
v3.24.1.1.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
 3 Months Ended
Mar. 31, 2024
shares
Accounting Policies [Abstract]  
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 0
v3.24.1.1.u2
Discontinued Operations (Details - Balance Sheet) - USD ($)
Mar. 31, 2024
Sep. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]    
Accounts payable and accrued expenses $ 12,000 $ 12,000
Total current liabilities from discontinued operations $ 12,000 $ 12,000
v3.24.1.1.u2
COMMON STOCK (Details Narrative) - $ / shares
Mar. 31, 2024
Sep. 30, 2023
Equity [Abstract]    
Common Stock, Shares Authorized 75,000,000 75,000,000
Common Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Common Stock, Shares, Issued 5,920,000 5,920,000
Common Stock, Shares, Outstanding 5,920,000 5,920,000
v3.24.1.1.u2
INTANGIBLE ASSETS (Details Narrative) - USD ($)
 12 Months Ended
Sep. 30, 2022
Mar. 31, 2024
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]      
Asset Impairment Charges $ 7,200    
Finite-Lived Intangible Assets, Net   $ 0 $ 0
v3.24.1.1.u2
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 6 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 28, 2022
Dec. 31, 2023
Sep. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Debt Forgiveness by Related Party $ 0 $ 51,192 $ 51,192    
Alborovi [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Accounts Payable, Other, Current       $ 0 $ 0
Zu [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Accounts Payable, Other, Current $ 0       $ 0
v3.24.1.1.u2
CONVERTIBLE NOTE PAYABLE (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Convertible Note 1 [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Convertible Notes Payable   $ 21,051
Debt Instrument, Interest Rate During Period   8.00%
Accrued Interest on Convertible Notes Payable $ 420  
Convertible Note 2 [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Convertible Notes Payable   $ 27,135
Debt Instrument, Interest Rate During Period   8.00%
Debt Instrument, Maturity Date   Dec. 31, 2029
Accrued Interest on Convertible Notes Payable 541  
Debt Instrument, Convertible, Conversion Price   $ 0.01
Convertible Note 3 [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Convertible Notes Payable   $ 10,602
Debt Instrument, Interest Rate During Period   8.00%
Debt Instrument, Maturity Date   Mar. 31, 2030
Accrued Interest on Convertible Notes Payable $ 0  
Medicale (PK) (USOTC:MCLE)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Medicale (PK).
Medicale (PK) (USOTC:MCLE)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Medicale (PK).